/biz/ - Business & Finance

>>17209042
SNSS is currently in their phase1b testing of Vecabrutinib, a BTK inhibitor that can treat people with CLL mutation (unlike it's competitors) and has significant value as a combination therapy with broader BTK inhibitors. Vecabrutinib was created by Biogen before BTK inhibition was proven to actually work against hematological cancers, and sold to SNSS for unbelievably cheap. Their 400mg cohort data is coming in Q1 2020, and their 300mg dose data showed near theraputic levels of BTK inhibition, meaning their data this time is likely to show tumor reduction and at least partial remissions. Other BTK inhibitors have shown massive value recently, like ARQL being bought out for 2.7 billion.